U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07549061) titled 'Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC' on April 16.
Brief Summary: To explore the efficacy and safety of vebreltinib plus platinum-doublet chemotherapy as first-line therapy in patients with driver gene-negative, locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET overexpression.
Study Start Date: March 30
Study Type: INTERVENTIONAL
Condition:
Lung Neoplasms
Intervention:
DRUG: Vebreltinib
vebreltinib，150mg，oral，bid
DRUG: Chemotherapy
Administered in accordance with the approved label
Recruitment Status: NOT_YET_RECRUITING
Sponsor: S...